NCT03663634

Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin B

Cytochalasin B Supplementation to ICSI Handling Medium

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 987 (actual)
• Sponsor: Ibn Sina Hospital · Other Government
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

Conditions

• Infertility

Interventions

Type	Name	Description
OTHER	Cytochalasin B use in ICSI handling medium	A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate

Timeline

• Start date: 2018-09-16
• Primary completion: 2019-07-20
• Completion: 2019-08-01
• First posted: 2018-09-10
• Last updated: 2019-08-07

Locations

1 site across 1 country: Egypt